Congratulations to Dr. Channing Der Dr. Jen Jen Yeh on the publication of their recent article, “Advances in RAS Therapeutics for Pancreatic Cancer.”
Their work highlights emerging treatments targeting KRAS mutations which are found in the vast majority of pancreatic cancers and discusses the promising early clinical results of daraxonrasib, a novel drug designed to target RAS-driven tumors. This research represents an exciting step forward in the development of new treatment options for pancreatic cancer patients.
Read the UNC School of Medicine Lineberger Comprehensive Cancer Center article highlighting their work, “Der, Yeh provide scientific context for recent progress in RAS therapeutics for pancreatic cancer.”
Read their published article, “Advances in RAS Therapeutics for Pancreatic Cancer,” in the New England Journal of Medicine (accessible with a free account or by subscription only).